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Kallikrein (PKa), generated by activation of its precursor prekallikrein
(PK), plays a role in the contact activation phase of coagulation and
functions in the kallikrein-kinin system to generate bradykinin.
The general dogma has been that the contribution of PKa to the
coagulation cascade is dependent on its action on FXII. Recently
this dogma has been challenged by studies in human plasma
showing thrombin generation due to PKa activity on FIX and also
by murine studies showing formation of FIXa-antithrombin com-
plexes in FXI deficient mice. In this study, we demonstrate high-
affinity binding interactions between PK(a) and FIX(a) using surface
plasmon resonance and show that these interactions are likely
to occur under physiological conditions. Furthermore, we directly
demonstrate dose- and time-dependent cleavage of FIX by PKa in
a purified system by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis analysis and chromogenic assays. By using normal
pooled plasma and a range of coagulation factor-deficient plas-
mas, we show that this action of PKa on FIX not only results in
thrombin generation, but also promotes fibrin formation in the
absence of FXII or FXI. Comparison of the kinetics of either FXIa-
or PKa-induced activation of FIX suggest that PKa could be a sig-
nificant physiological activator of FIX. Our data indicate that the
coagulation cascade needs to be redefined to indicate that PKa can
directly activate FIX. The circumstances that drive PKa substrate
specificity remain to be determined.
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Hemostasis is a highly adaptive process that controls bloodfluidity and rapidly induces hemostatic plug formation after
vascular injury to stop or limit bleeding (1, 2). Traditionally, the
coagulation cascade has been recognized as the result of trig-
gering of the tissue factor (TF) (extrinsic) pathway or following
contact activation, leading to initiation of the intrinsic pathway
(3, 4). The extrinsic pathway is triggered on damage to a vessel
wall and exposure of TF, which promotes activation of Factor
(F) VII to FVIIa. TF/FVIIa form a complex which activates FX
to FXa, allowing FXa to associate with cofactor FVa to form the
prothrombinase complex, which serves to convert prothrombin
into thrombin. Thrombin then cleaves fibrinogen to form fibrin,
which polymerizes to form a network of fibrin fibers. The in-
trinsic pathway of coagulation is initiated by activation of FXII
following exposure to negatively charged surfaces or molecules
such as RNA, DNA, misfolded proteins, and polyphosphates
(polyP) (5–10). Both FXII and prekallikrein (PK) of the intrinsic
pathway possess zymogenic proteolytic activity that can initiate
reciprocal activation to FXIIa and kallikrein (PKa), respectively.
While this can occur in solution, the reaction is enhanced on a
surface (11, 12). In the presence of a surface reciprocal activa-
tion of FXII and PK is amplified through the cofactor activity of
high molecular weight kininogen (HK) (13, 14). The FXIIa
generated stimulates the intrinsic pathway of coagulation by ac-
tivating FXI, which then converts FIX to FIXa, and FIXa acti-
vation of FX to FXa, at which point the intrinsic and extrinsic
pathways converge.
In addition to its role in the intrinsic pathway of coagulation,
PKa also functions in the kallikrein-kinin system by cleaving HK,
releasing the vasoactive peptide bradykinin (BK) (15). PK defi-
ciency is associated with prolonged activated partial thrombo-
plastin time (aPTT) (16, 17), but clinically, most PK-deficient
patients have no hemostatic defect (18, 19). Murine in vivo PK
deficiency is recognized to cause delayed arterial thrombosis in-
duced by application of ferric chloride (20), while selective re-
duction of PK in vivo using antisense oligonucleotides in mice
results in reduced thrombus formation without a bleeding defect
(21). A study by Stavrou et al. (22) demonstrated that reduction
of thrombosis in PK-deficient mice could be attributed to a
mechanism other than reduced contact activation. The authors
concluded that in the absence of PK, decreased production of
BK in the PK-deficient mice was associated with reduced ex-
pression of the bradykinin B2 receptor (B2R), which led to a
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compensatory overexpression of Mas receptor. This was associ-
ated with increased plasma prostacyclin, which resulted in up-
regulation of vascular transcription factors sirtuin-1 (Sirt1) and
Kruppel-like factor 4 (KLF4) and a reduction in vascular TF
(22). Within the coagulation cascade, the key substrate of PKa
was considered to be FXII, leading to FXIIa activation of FXI
and ultimately to thrombin generation. Early studies performed
in a purified system identified activation of FIX by PKa (23) but
reported that FXIa was more efficient at cleaving FIX (24). Sun
and Gailani (25) demonstrated cleavage of FIX by PKa in a
purified system, and Puy et al. (26) reported that FXIIa activated
with polyP could reduce clotting time in FXI-deficient plasma by
a mechanism dependent on FIX but independent of FXI . More
recently, Visser et al. (27) demonstrated indirectly (using a specific
PKa inhibitor in FXI-deficient plasma) that PKa contributes to
FXIa-independent activation of FIX, as determined by measur-
ing FIXa-antithrombin and FXa-antithrombin complexes, throm-
bin generation, and aPTT prolongation. Furthermore, Visser et al.
showed elevated FIXa-antithrombin complex levels when mice
deficient in FXI were challenged with ellagic acid and long-chain
polyP, which were reduced in the presence of a specific PKa
inhibitor. Noubouossie et al. (28) also indirectly demonstrated
the ability of PKa to activate FIX.
The objectives of the current study were to directly demonstrate
an interaction between PK(a) and FIX(a), to characterize the ac-
tivation of FIX by PKa in purified and plasma-based systems, and to
determine whether PKa activation of FIX leads to fibrin formation.
Results
PKa-Induced Thrombin Generation and Fibrin Formation Occur in the
Absence of FXII and FXI. To assess whether PKa could initiate
thrombin generation independently of its FXII-activating activ-
ity, thrombin generation was measured in FXII-deficient plasma
spiked with increasing concentrations of PKa in the presence of
phospholipids (PLs) and CaCl2. The highest concentration of
PKa used in these assays was 581 nM, to reflect the plasma con-
centration of its precursor PK (15). Compared to normal pooled
plasma (NPP) (Fig. 1A), thrombin generation occurred but was
less efficient in FXII-deficient plasma (Fig. 1B). The addition of
corn trypsin inhibitor (CTI) indicated that no residual FXII was
contributing to PKa-induced thrombin generation (Fig. 1B). In
FXI-deficient plasma with and without CTI (Fig. 1 C and D),
thrombin generation occurred but was delayed compared to NPP
and FXII-deficient plasma. PKa failed to induce thrombin gener-
ation in FIX-deficient (Fig. 1E) and FX-deficient (Fig. 1F) plasmas.
To determine whether the amount of thrombin generated by
PKa in the absence of FXII was able to form fibrin, clot for-
mation was monitored by measuring turbidity. For this purpose,
clotting in NPP and plasmas deficient in FXII, FXI, FIX, and FX
was triggered by recalcification and addition of increasing con-
centrations of PKa in the presence of PLs. The results confirmed
that PKa initiates the intrinsic pathway in a dose-dependent
manner in NPP (Fig. 1G), and triggers clot formation even in
the absence of FXII or FXI (Fig. 1 H and I). Prolonged lag times
were observed in FXII- and FXI-deficient plasmas (Fig. 1 H and
I) compared to NPP, consistent with the less efficient thrombin
generation observed in these plasmas (Fig. 1 B–D). In contrast to
thrombin generation profiles showing no thrombin generation in
FIX- and FX-deficient plasmas (Fig. 1 E and F), some fibrin
formation was observed (Fig. 1 J and K), albeit only at high PKa
concentrations. It is possible that minute amounts of thrombin
are produced in FIX- and FX-deficient plasmas that are too low
for detection but sufficient to initiate fibrin formation.
PKa Directly Cleaves FIX in a Time- and Dose-Dependent Manner and
Does Not Require Cofactors. To determine which proteins of the
coagulation cascade downstream of FXII were activated by PKa,
cleavage assays were performed by incubating FX, FXI, pro-
thrombin, or FIX with a concentration series of PKa. Cleavage
products were then analyzed by reducing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). PKa did not
cleave FX or FXI at any of the PKa concentrations (Fig. 2 A and
B). The additional bands observed in the lanes where high con-
centrations of PKa were used were consistent with the migration
of PKa only. In contrast, PKa cleaved prothrombin (Fig. 2C) and
FIX (Fig. 2D), demonstrating cleavage of these zymogens to
generate their activated enzymes. Prothrombin was cleaved at
PKa concentrations ≥64.5 nM, while FIX was cleaved by
concentrations ≥21.5 nM PKa.
We next investigated the generation of FIXa over time by PKa
by incubating FIX (0.5 mg/mL) with PKa (65 nM) for up to
240 min in the presence of CaCl2. Samples were assessed by
reducing SDS-PAGE and demonstrated cleavage of FIX to FIXa
over time (Fig. 2E). Having demonstrated that PKa activation of
FIX occurred in the presence of CaCl2, we next investigated the
cofactor-dependency of this reaction in chromogenic substrate
assays using purified FIX and PKa proteins. FIX and PKa pro-
teins were first assessed for purity by mass spectrometry analysis
to exclude the possibility of contaminating proteins contributing
to chromogenic substrate cleavage. These analyses confirmed
that FIX protein did not contain any contaminants, while PKa
contained FXII (SI Appendix, Table S1), which was not of con-
cern, as other groups have demonstrated that FXII is not able to
cleave FIX to FIXa (26, 27). Assays were performed with com-
binations of PLs, CaCl2, and ZnCl2 in the presence and absence
of HK to determine the effect of these combinations on FIX
activation by PKa. Substrate cleavage occurred without PLs,
CaCl2, or ZnCl2, and the presence of HK did not have an ac-
celerating effect on chromogenic substrate cleavage in samples
containing FIX+PKa (Fig. 2F). A further experiment performed
in the presence of EDTA confirmed that the activation of FIX by
PKa does not require CaCl2 (SI Appendix, Fig. S1).
Rate of chromogenic substrate cleavage by FIXa increased in
samples as PKa concentration increased (Fig. 2G), demonstrat-
ing that PKa cleaves FIX in a dose-dependent manner. In these
assays, increasing concentrations of PKa were added to FIX be-
fore the immediate addition of chromogenic substrate S-2765.
Samples containing only PKa were run in parallel, and the signals
from these samples were used for baseline subtraction (Fig. 2G).
Subsequently, kinetic parameters of PKa activation of FIX
were determined alongside FXIa activation of FIX to allow
comparison of these two FIX activators. The Km values for PKa
and FXIa were not significantly different; the Km for PKa acti-
vation of FIX was 154.4 nM (95% confidence interval [CI] 95.32
to 248.1 nM), and that for FXIa was 299.4 nM (95% CI, 190.6 to
477.5 nM). The kcat of PKa and FXIa were significantly differ-
ent: 0.022 s−1 (95% CI 0.019 to 0.026 s−1) for PKa and 0.285 s−1
(95% CI, 0.244 to 0.339 s−1) for FXIa. The kcat/Km for PKa and
FXIa also differed significantly (Table 1), suggesting that FXIa is
∼6.5-fold more efficient as an activator of FIX (0.951/0.144 =
6.6), which is accounted for by differences in the kcat. Kinetic
parameters are summarized in Table 1, and the graphs for de-
termining rates of FIX activation by PKa and FXIa are presented
in SI Appendix, Fig. S2. However, plasma concentrations of PK
and FXI are 581 nM and 30 nM, respectively; that is, PK is 19.4-
fold more abundant than FXI. Therefore, given the plasma
concentration of FIX of 89 nM, we calculate that if 1% of plasma
FXI were activated (0.3 nM FXIa), then the rate of FIX acti-
vation would be 0.020 nM/s, while if 1% of plasma PK were
activated (5.81 nM PKa), then the rate of FIX activation by PKa
would be 0.047 nM/s. Under these conditions, activation of
FIX by PKa would exceed that by FXIa by 2.3-fold (rate = E0
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Fig. 1. PKa can initiate thrombin generation and fibrin formation independently of FXII. Plasmas deficient in proteins of the clotting cascade were assessed
for thrombin generation and fibrin formation when initiated with PKa (0.797 to 581 nM). (A–F) Thrombin generation performed after recalcification with
16.7 mM CaCl2 in the presence of 10 μM PLs. Thrombin generation in NPP (A), FXII-deficient plasma with CTI (B), FXI-deficient plasma (C), FXI-deficient plasma
with CTI (D), FIX-deficient plasma (E), and FX-deficient plasma (F). Thrombograms show mean thrombin generated. n = 3. (G–K) Turbidimetric experiments were
performed in plasma in the presence of 10 mM CaCl2 and 10 μM PLs. Fibrin clot formation over time was measured by the change in absorbance at 340 nm in NPP
(G), FXII-deficient plasma (H), FXI-deficient plasma (I), FIX-deficient plasma (J), and FX-deficient plasma (K). Data are presented as mean ± SD, n = 3.
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× kcat × [FIX]/(Km + [S]), where E0 is the concentration of PKa
or FXIa and [S] is the concentration of FIX).
Generation of FIXa by PKa Occurs in the Presence of FXII. To deter-
mine the physiological relevance of PKa cleavage of FIX, we
monitored the formation of cleavage products in assays in which
PKa was present with FXII, PKa’s primary substrate. Generation
of αFXIIa, βFXIIa, and FIXa was evident by PKa in a time-
dependent manner (SI Appendix, Fig. S3).
PKa Binds to FIX with High Affinity.We sought to define the binding
affinities involved in the interaction of PK(a) with FIX(a) using
surface plasmon resonance (SPR). These experiments determined
high-affinity interactions of PK and PKa for FIX (Fig. 3 A and B)
and FIXa (Fig. 3 C and D). The affinity of interaction, KD, for PK
binding to FIX was 2.167 ± 0.003 nM, and to FIXa was 0.492 ±
0.001 nM (KD ± SD). The KD for PKa binding to FIX was 1.701 ±
0.003 nM, and to FIXa was 0.700 ± 0.010 nM (Fig. 3 A–D). KD
values and rates of association (Ka) and dissociation (Kd) are
summarized in Table 2.
The high-affinity interaction of PK with FIX and FIXa
prompted the question of whether binding would occur in cir-
culation, considering that PK circulates predominantly (∼70 to
80%) in a 1:1 noncovalent complex with HK (29). SPR studies
showed a high-affinity interaction of PK and PKa for HK (Ta-
ble 2). FIX was able to form a complex with PK in the presence
of HK, as indicated by the increase in resonance units (RU) in
the PK+HK+FIX sample compared with the PK+HK sample
(Fig. 3E), which was approximately equal to the signal from
Fig. 2. PKa can selectively cleave FIX in a dose- and time-dependent manner. (A–D) The ability of PKa to cleave zymogen FX, FXI, prothrombin (FII), and FIX
was determined by incubating reaction mixtures containing 0.5 mg/mL zymogen protein with a concentration series of PKa (2.39 to 581 nM), in the presence
of 1.5 mM CaCl2 and 10 μM PLs. Samples were incubated for 1 h at 37 °C before analysis by SDS-PAGE under reducing conditions. PKa titration incubated with
FX (A), FXI (B), FII (C), and FIX (D). (E) The time dependency of FIX cleavage by PKa was assessed by incubating 0.5 mg/mL FIX with 65 nM PKa in the presence
of 1.5 mM CaCl2 for up to 240 min. Samples were assessed by SDS-PAGE under reducing conditions. (F) 5 nM PKa and 300 nM FIX protein were mixed in the
presence of a variety of buffer conditions containing PLs (10 μM), CaCl2 (2.5 mM), and ZnCl2 (10 μM). Each of these conditions was assessed in the presence
(blue bars) and absence (green bars) of 12 nM HK. Cleavage of chromogenic substrate S-2765 by samples was measured for 1 h. Data represent the rate of
chromogenic substrate cleavage over 1 h, mean ± SD; n = 3. (G) 300 nM FIX protein was added to 0.726 to 5.81 nM PKa in the presence of CaCl2 (2.5 mM) and
ZnCl2 (10 μM), followed by the addition of chromogenic substrate S-2765. Samples containing only PKa (0.726 to 5.81 nM) were run in parallel. Data represent
PKa subtracted, mean ± SD; n = 3. In A–E, positions of molecular mass standards (in kDa) are shown to the left of each gel image.
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FIX+PK binding (Fig. 3A). Similarly, SPR data suggested that
PKa, FIX, and HK were able to form a complex (Fig. 3F). In
contrast to FIX, FIXa contributed no more binding to PK or
PKa when HK was present (Fig. 3 G and H), suggesting that
FIXa does not form a complex with PK(a) and HK. To sum-
marize, these data show that PK+HK+FIX and PKa+HK+FIX
complexes can exist, but not when FIX is activated; that is,
PK+HK+FIXa and PKa+HK+FIXa complexes cannot exist.
We next investigated the interaction of PK and PKa with
prothrombin, as our data demonstrated cleavage of prothrombin
by PKa (Fig. 2C). No binding of PK or PKa to prothrombin was
detected (Fig. 3 I and J and Table 2).
Discussion
Despite early studies demonstrating an ability of PKa to cleave
FIX (23, 24, 30), the general dogma for many years was that
PKa’s role in coagulation was solely FXII-dependent, ultimately
resulting in thrombin generation via FXIa generation. Puy et al.
(26) showed the possible potential for PKa to contribute to clot
formation in a manner independent of FXI, by demonstrating
that long-chain polyP-activated FXII could generate PKa, which
subsequently activated FIX. More recently, Visser et al. (27) and
Noubouossie et al. (28) have provided indirect evidence through
the measurement of FIXa-antithrombin complexes that PKa can
activate FIX in an FXI-independent manner. In this report, we
provide direct evidence of high-affinity binding interactions between
PK(a) and FIX(a). We also demonstrate time-and dose-dependent
activation of FIX by PKa that ultimately causes thrombin genera-
tion and results in fibrin formation in an FXI-independent manner.
Furthermore, we determined kinetic parameters of FIX activation
by both PKa and FXIa, allowing direct comparison of the two FIX
activators under the same experimental conditions.
To confirm that PKa generates thrombin independent of its
activity on FXII, we first measured thrombin generation in FXII-
and FXI-deficient plasmas triggered with a concentration series
of PKa. As expected, PKa was most efficient at generating thrombin
when FXII was present in NPP. However, in the absence of FXII
or FXI, it was still possible to observe dose-dependent thrombin
generation. The addition of CTI did not affect thrombin gener-
ation in the FXII- or FXI-deficient plasmas, indicating that the
thrombin generated was not FXII-dependent. When PKa was
added to FIX- or FX-deficient plasmas, no thrombin was gen-
erated, suggesting that FIX and FX are required to generate
detectable levels of thrombin. These findings were confirmed by
Noubouossie et al. (28), who demonstrated that purified PKa
initiated thrombin generation in NPP and FXII- and FXI-
deficient plasmas, but not in FIX-deficient plasma. To expand
on this, we performed experiments to characterize the role of
PKa on clot formation using turbidity analyses. Using FXII- or
FXI-deficient plasma, PKa was able to induce clot formation,
albeit with lower efficiency at the lower concentrations of PKa.
In addition, we showed that despite the absence of thrombin
generation in FIX- and FX-deficient plasmas, there was fibrin
formation at the highest PKa concentrations. Since FXIa has
been shown to activate FX (26) and induce thrombin generation
in FIX-deficient plasma by activating FV and FX (31), it is
possible that minute amounts of thrombin are produced in FIX-
deficient plasma by these mechanisms, which are not detectable
by thrombin generation but are sufficient for fibrin formation.
Fibrin formation in FX-deficient plasma at the highest PKa
concentration may be a result of direct cleavage of prothrombin
by PKa, as has been observed by others (26, 32, 33). However, we
do not anticipate that this occurs physiologically. Together, the
thrombin generation and turbidity experiments confirm that PKa
can act independently of FXII and FXI to result in the genera-
tion of thrombin and in fibrin formation.
Having demonstrated that PKa could initiate clotting in the
absence of FXII and FXI, we next sought to determine which
zymogens of the coagulation cascade downstream of FXII could
be cleaved when incubated with increasing concentrations of PKa.
PKa cleaved FIX to FIXa and prothrombin to thrombin, albeit at
higher PKa concentrations than were required for cleavage of
FIX. Given that higher concentrations of PKa were required to
cleave prothrombin, it is likely that this process has relatively less
physiological significance than PKa activation of FIX. Further-
more, we did not detect any binding of PK or PKa to prothrombin
in our SPR experiments, suggesting that PKa cleavage of pro-
thrombin is an inefficient reaction occurring only in the presence
of a high PKa concentration. At high concentrations, PKa has
trypsin-like qualities, which would allow cleavage of prothrombin
by PKa despite the low affinity of the proteins for each other.
In contrast to the absence of PKa binding to prothrombin in
SPR studies, we demonstrated high-affinity binding interactions
between PK(a) and FIX(a), with binding affinities in the low
nanomolar range. FIX circulates in plasma at ∼89 nM (24), and
thus the interaction with PK and PKa is likely to occur under
physiological conditions and potentially play a role in thrombin
generation and clot formation under appropriate conditions. Puy
et al. (26) showed that this route is likely to be relevant in the
context of a surface such as long-chain polyP during bacterial
infections, and Visser et al. (27) demonstrated that it occurs
in vivo in FXI-deficient mice following treatment with long-chain
polyP. It is plausible that other surfaces may also drive this role
of PKa activity toward FIX in physiological circumstances. Fur-
ther SPR experiments with HK indicated complex formation
between PK(a), HK, and FIX, but not FIXa. These data suggest
that PK, which circulates with HK (29), can bind FIX, and that
once activation occurs, active FIXa no longer binds. It is necessary
to consider the limitations of the SPR system when interpreting
these data. Although we detected an increased binding signal
suggesting formation of a complex between PK(a), HK, and FIX,
due to the unlabeled nature of the SPR system, it is not possible to
say with complete certainty that FIX was not binding to HK in
these experiments. However, to our knowledge, there have been
no reports of FIX-HK binding, and thus it is much more likely that
we detected FIX binding to PK(a) in the presence of HK.
Subsequently, we investigated the activation of FIX by PKa by
direct measurement of FIXa generation in chromogenic sub-
strate assays. To be confident in the interpretation of substrate
cleavage assays using purified FIX and PKa, we submitted samples
of these proteins for mass spectrometry analysis to identify any
possible contaminants that could have contributed to substrate
cleavage. We found that the PKa sample was contaminated with
FXII, while FIX protein was free from contamination. The pres-
ence of FXII in PKa samples could not have affected chromogenic
substrate cleavage (by activating FIX in place of/in addition to
Table 1. Summary of kinetic parameters determined for the
activation of FIX by PKa and FXIa
Parameter
PKa FXIa
Mean 95% CI Mean 95% CI
Vmax, nM/s 0.0646 0.0560–0.0749 0.0427 0.0365–0.0509
kcat , s−1 0.0222 0.0193–0.0258 0.2847 0.2435–0.3394
Km, μM 0.1544 0.0953–0.2481 0.2994 0.1906–0.4775
kcat/Km, μM−1s−1 0.1439 0.2021–0.1040 0.9508 1.2777–0.7108
Kinetic parameters for PKa and FXIa activation of FIX were determined in
reactions in which 2.905 nM PKa and 0.15 nM FXIa were incubated with a
concentration series of FIX, and cleavage of chromogenic substrate S-2765
was monitored over time. Data are the mean of data from three indepen-
dent experiments, each performed in triplicate.
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PKa), as others have shown that FXII(a) cannot activate FIX
directly (26, 27). Our data indicate that the activation of FIX by
PKa occurs in the absence of CaCl2, supporting the conclusion
reached in the earlier studies of Osterud et al. (23, 24) and Puy
et al. (26). Additionally, our data demonstrate that this reaction can
occur in the absence of ZnCl2 and PLs, with vesicles containing 60%
Fig. 3. PK(a) binds to FIX(a) with high affinity. Binding kinetics and affinities of the interaction of FIX and FIXa (± HK), and prothrombin (FII) with PK and PKa
were studied by SPR using a Pioneer system. FIX (A and B) and FIXa (C and D) proteins were injected over a PK- or PKa-immobilized surface. Data are mean ±
SEM; n = 3. (E–H) Experiments were also performed in the presence of HK. FIX was preincubated with HK and flowed over a PK-immobilized (E) or
PKa-immobilized (F) surface. FIXa was preincubated with HK and injected over a PK-immobilized (G) or PKa- immobilized (H) surface. (I and J) Binding of FII to
PK (I) and PKa (J). n = 1 for experiments in E–J.
Table 2. Summary of binding affinities and kinetics of binding to PK and PKa
Parameter
PK PKa
Ka ± SD, M
−1s−1 Kd ± SD, s
−1 KD ± SD, nM Ka ± SD, M
−1s−1 Kd ± SD, s
−1 KD ± SD, nM
FIX 1.103 ± 0.001e5 2.39e-4 2.167 ± 0.003 1.342 ± 0.002e5 2.28e-4 1.701 ± 0.003
FIXa 1.311 ± 0.001e5 6.45 ± 0.02e-5 0.492 ± 0.001 1.341 ± 0.005e5 9.30 ± 0.1e-5 0.700 ± 0.010
HK 1.520 ± 0.004e5 3.73 ± 0.01e-5 0.245 ± 0.001 1.037 ± 0.004e5 2.82e-5 0.272 ± 0.001
FII No binding No binding
The binding of FIX, FIXa, HK, and FII to PK and PKa was investigated by SPR, and affinity (KD) and rate constants for association (Ka) and dissociation (Kd)
were determined.
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1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 20% 1,2-
dioleoylsn-glycero-3-phosphoethanolamine (DOPE), and 20% 1,2-
dioleoyl-sn-glycero-3-phosphoserine (DOPS), and, further, that the
presence of HK does not have any effect on the reaction. In a study
of the activation of FXII by PKa, Wang et al. (34) reported a re-
quirement of HK for PKa; however, our data suggest that HK has
little effect on the FIX-activating activity of PKa. In summary, our
data show that the activation of FIX by PKa can happen in the
absence of a surface or in the presence of PLs, and that HK plays no
role as an accelerating protein cofactor under these conditions.
However, given the SPR data showing formation of a trimolecular
complex of PK(a), HK, and FIX, it may be that HK has a role in
FIX activation in the presence of other surfaces, such as long-chain
polyP (35, 36).
A more detailed analysis of the kinetic characteristics of PKa
activation of FIX, and comparison with FXIa activation of FIX
revealed that PKa may contribute significantly to FIXa genera-
tion under physiological conditions. The catalytic efficacy of FXIa
activation of FIX was ∼6.5-fold more efficient than the PKa ac-
tivation of FIX. However, given that the plasma concentration of
PK is ∼19.4 times more abundant than FXI, if similar propor-
tionate amounts of PKa and FXIa are generated with respect to
percentage of each zymogen activated, then according to the
formula rate = E0 × kcat × [FIX]/(Km + [S]) (where E0 is the
concentration of PKa or FXIa and [S] is the concentration of
FIX), PKa is ∼2.3 fold more likely than FXIa to result in FIX
activation, under our experimental conditions. It remains to be
determined if other surfaces/proteins influence these reactions.
PK has close sequence homology with FXI; both genes evolved
from a common ancestor, and the proteins share ∼58% sequence
homology (37). Analogous to FXI, PK is composed of four apple
domains that form the heavy chain of PK and a C-terminal
protease domain (38). Given the similarity between FXI and
PK, it is perhaps not surprising that both proteins can activate
FIX. A study by Sun and Gailani (25), in which recombinant FXI
proteins were expressed with each of the four apple domains of
the heavy chain individually replaced with the corresponding
domain from the homologous PK, suggested that FXIa could be
∼45 times more efficient than PKa as an ex vivo activator of FIX;
however, that study did not compare WT PK with FXI proteins
directly. Others have found larger differences in the FIX-activating
abilities of FXIa and PKa. Osterud et al. (24) reported that FXIa
was ∼20,000 times more active than PKa at activating FIX in
their experimental setup. However, that early study was based on
subsampling of a single set of experimental reaction conditions
for FXIa or PKa with FIX, in contrast to the detailed kinetic
analysis that we have performed. More recently, Visser et al. (27)
demonstrated that inhibition of PKa did not inhibit FIXa gen-
eration in normal plasma, compared with a large decrease in the
detection of FIXa in FXI-deficient plasma. Our data show that
FXIa is ∼6.5 times more efficient than PKa as an activator of
FIX, which is largely due to the significantly higher kcat of FXIa.
However, in the context of the greater PK plasma concentrations
compared to FXI, it is plausible that PKa contributes signifi-
cantly to the overall generation of FIXa.
These data suggest that PKa is a more versatile protease than
originally suspected in the context of hemostasis and thrombosis.
PKa contributes to thrombin generation primarily through acti-
vation of FXII, although we have demonstrated that PKa acti-
vation of FIX can occur independently of FXII and FXI. It
remains to be determined under what conditions PKa activates
FIX over FXII, or whether these activation events occur con-
currently physiologically. It seems plausible that this event is
physiological, given the tight binding interaction between PK(a)
and FIX(a). PK could potentially be a carrier protein for FIX,
bringing FIX and PKa in close proximity to a surface where clot
formation is likely to occur. The implications of PKa activation
of FIX are relevant to the development of new anticoagulants
targeting FXI and FXII (39, 40).
It has previously been considered that FXIa inhibitors would
target all the actions of FXIIa. However, the mechanism of FIX
activation by PKa bypasses FXI. Therefore, it is possible that
FXIIa inhibitors may contribute to reduced PKa generation,
which in turn would lead to reduced FIX activation and subse-
quent thrombin generation, independent of FXIa activity. To
summarize, it is highly plausible that PKa activation of FIX is a
mechanism responsible for thrombin generation and fibrin for-
mation, and it needs to be considered in a revised model of the
coagulation cascade (Fig. 4).
Materials and Methods
Chemicals. PKa, PK, HK, and CTI were obtained from Enzyme Research
Laboratories. Prothrombin, FIX, FX, FXI, and FXII were purchased from
Haematologic Industries. Thrombin calibrator and FluCa kit (buffer and
substrate) were purchased from Stago. FIX-, FX-, FXI-, and FXII-deficient
plasmas were obtained from George King Bio-Medical. CaCl2, ZnCl2, NaCl,
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes), bovine serum
albumin, and InstantBlue gel stain were purchased from Sigma-Aldrich.
NuPAGE 4–12% Bis-Tris Protein Gels, MES SDS running buffer, LDS sample
buffer, and sample reducing agent were obtained from Thermo Fisher Sci-
entific. Precision Plus Protein Dual Color Standards was obtained from Bio-
Rad. Chromogenic substrate S-2765 was obtained from Quadratech Diag-
nostics. The synthetic PLs DOPC, DOPS, and DOPE were purchased from
Avanti Polar Lipids. Unless stated otherwise, the buffer used was Hepes-
buffered saline (HBS) containing 20 mM Hepes and 137 mM NaCl, pH 7.4.
PL Preparation. PL vesicles were composed of 60%DOPC, 20%DOPS, and 20%
DOPE and were prepared as described previously (41). In brief, PLs were dried
under nitrogen gas, resuspended in HBS, vortexed, and extruded through a
1-μm membrane.
NPP Samples. Whole blood was collected from 30 healthy volunteers into
0.109 M trisodium citrate-treated tubes. Informed written consent was
obtained from each volunteer in accordance with the Declaration of Helsinki.
Ethical approval was obtained from the University of Leeds Medical School
Ethical Committee (HSLTLM/12/045). Free flow or minimal suction was used
during blood sampling. Blood samples were centrifuged twice at room tem-
perature: 30 min at 3,000 × g, followed by 10 min at 11,000 × g. Platelet-poor
plasma supernatants were transferred into clean polypropylene tubes using
Pasteur pipettes. Pooled plasma was divided into 0.5-mL aliquots, snap-frozen
in liquid nitrogen, and stored at −80 °C.
Thrombin Generation. Thrombin generationwasmeasured using a Thrombinoscope
(Stago) and performed in Immulon 2HB, round-bottom 96-well plates (Thermo
Fisher Scientific). In brief, 60 μL of each plasma sample was spiked with 2.39 to
581 nM PKa in 20 μL with 10 μM PLs. Samples containing 20 μL of thrombin
calibrator (Diagnostica Stago) were run in parallel with each cycle of test
sample. Thrombin generation was triggered by the addition of PKa, followed
by 20 μL of calcium–fluorogenic substrate reagent (16.7 mM calcium and
0.42 mM substrate final reaction concentrations). In some experiments, CTI (1.6
μM) was added to the plasma samples to block FXII activity. All concentrations
are final. Thrombograms were produced by monitoring fluorescence at 37 °C
at 20-s intervals for 120 min. Each set of conditions was tested in triplicate.
Turbidity Measurements of Fibrin Formation. Fibrin polymerization in plasma
samples was measured in clear flat bottom polystyrene 96-well plates
(Thermo Fisher Scientific) by monitoring turbidity at 340 nm every 12 s for 1 h
using a PowerWave HT Microplate Spectrophotometer (BioTek). Citrated
plasma solutions (25% plasma) were added to a 96-well polystyrene plate
(Thermo Fisher Scientific), and gelation was initiated with CaCl2 (10 mM) in
combination with a range of PKa concentrations (0.797 to 581 nM). Exper-
iments were performed in the presence of 10 μM PL vesicles (all concen-
trations are final). Each set of conditions was tested in triplicate.
Zymogen Cleavage by PKa, Assessed by SDS-PAGE. Samples of zymogen (FX,
FXI, prothrombin, or FIX; 0.5 mg/mL), PKa (2.39 to 581 nM), 10 μM PLs, and
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1.5 mM CaCl2 were incubated at 37 °C (all concentrations are final). The
addition of reducing agent and sample buffer to samples stopped the re-
actions. Samples were boiled at 95 °C for 10 min before loading. Gels were
run for 50 min at 200 V and stained overnight using InstantBlue gel stain and
then imaged on Syngene G:BOX Chemi and GeneSys software.
Cleavage of FIX by PKa in the Presence of FXII. Here 6 μM zymogen FIX and FXII
were incubated with 100 nM PKa in the presence of 10 μM PLs, 1.5 mM CaCl2,
10 μM ZnCl2, and 100 nM HK at 37 °C for up to 120 min (all concentrations are
final). Reactions were stopped by the addition of reducing agent and boiling
for 10 min at 95 °C, and samples were assessed by SDS-PAGE under reducing
conditions. Band intensities on the stained gel were determined using ImageJ.
Activation of Factor IX by Plasma PKa in Chromogenic Assays. FIX and PKa
proteins were assessed for purity by mass spectrometry analysis at the Bio-
molecular Mass Spectrometry Facility of the University of Leeds (SI Appendix).
The activation of zymogen FIX by PKa was assayed in clear polystyrene
96-well flat-bottom plates (Thermo Fisher Scientific) with 300 nM FIX and
5 nM PKa. Conditions tested included the addition of purified HK (12 nM),
PLs (10 μM), CaCl2 (2.5 mM), and ZnCl2 (10 μM). The generation of FIXa was
determined by monitoring cleavage of S-2765 (5 mM) using a PowerWave
HT Microplate Spectrophotometer (BioTek) at 405 nm every 12 s for 1 h. For
PKa dose–response experiments, a concentration curve of PKa (0.726 to 5.81
nM) was added to the plate, with and without FIX (300 nM) with CaCl2
(2.5 mM) and ZnCl2 (10 μM). Cleavage of chromogenic substrate S-2765 (5
mM) was measured as described above. For experiments with EDTA, FIX (300
nM) and PKa (5 nM) were added to wells containing CaCl2 (1.5 mM) or EDTA
(1 mM). Chromogenic substrate S-2765 was added, and substrate cleavage
was measured as described above.
Determination of Kinetic Parameters. PKa (2.905 nM) and FXIa (0.15 nM) were
added to a concentration series of FIX (37.5 to 1,200 nM) before the addition
of 5 mM S-2765, in the presence of 2.5 mM CaCl2 and 10 μM ZnCl2 (all final
concentrations). The generation of FIXa was determined by monitoring the
cleavage of S-2765 as described above. Rates of FIX activation by PKa and
FXIa (in pM/s) were determined using a Shiny app for calculating zymogen
activation rates (version 0.62) (42). This app uses predetermined parameters
for the action of FIXa on the chromogenic substrate S-2765 to calculate the
initial rate of FIXa generation in pM/s from reaction time courses using
slopes of absorbance vs. time squared. The values for Km (40.46 mM) and
Fig. 4. The coagulation cascade. The intrinsic pathway is initiated after activation of FXII by contact with a negatively charged surface. FXIIa can activate PK
to PKa, and PKa can activate more FXII. In the presence of a surface, reciprocal activation of FXII and PK to FXIIa and PKa is amplified by cofactor HK. FXII has
intrinsic proteolytic activity that is able to activate PK without a surface (purple dotted arrows). Similarly, PK has proteolytic activity that can activate FXII, but
this reaction requires a surface (purple dotted arrows). Following FXIIa activation, FXI is activated to FXIa, and FIX is activated to FIXa. The extrinsic pathway is
initiated following tissue damage and exposure of tissue factor. Both pathways converge at the activation of FX to FXa and conversion of prothrombin to
thrombin. Thrombin cleaves fibrinogen to fibrin, which polymerizes to form fibrin fibers and also activates FXIII, which introduces cross-links into the fibrin
network, stabilizing it. Many reactions of the coagulation cascade require calcium (Ca2+) or PLs (yellow circles). We and others have demonstrated that PKa
can directly activate FIX, bypassing FXI (red dashed arrow). Zymogens are indicated by roman numerals, and their activated forms end with an “a”.
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kcat (2.43 s−1) for FIXa on S-2765 were not well estimated from fitting of
Michaelis–Menten curves (GraphPad Prism version 8) because the Km was so
high. However, when rates were measured at [S] << Km, the individual
parameters of kcat and Km were not important; only their ratio was important,
and this could be estimated from rate ∼ [Eo]·[S]·kcat/Km, which is linear where
[S] << Km. Therefore, linear fits for initial rates of time squared plots were
performed over the first 20 min of the reaction, and a 60-s delay was included
for the time between reaction mixing and the first reading.
SPR. SPR was performed using the Pall/ForteBio Pioneer biosensor platform
(Molecular Devices) at a temperature of 22 °C. More details are provided in SI
Appendix. Assay running buffer (RB), containing 10 mM Hepes, 140 mM
NaCl, 1.5 mM CaCl2, and 40 μM ZnCl2 pH 7.4, was filter-sterilized and
degassed. A COOHV chip was installed into the Pioneer platform and primed
three times using RB. The surface was preconditioned for amine coupling,
and proteins were immobilized to the sensor surface using a standard amine
coupling method (43). Phenylmethylsulfonyl fluoride (PMSF)-treated PK was
immobilized to flow cell (FC)-1, and PKa was immobilized to FC-3. Remaining
active NHS-ester bonds on FC-1, FC-2, and FC-3 were blocked by injection of
1 M ethanolamine (pH 8.5) at 20 μL/min for 5 min. Final immobilization levels
of PK and PKa were engineered to provide a theoretic binding maximum
(RMAX) of 100 to 200 RU. Three prime functions were performed before
analysis using RB. All analytes were diluted to 250 nM in RB and injected
over the sensor surface using a OneStep 100% loop injection, with Taylor
dispersion to create a concentration gradient through the capillary tube
before entering the FC, at a flow rate of 30 μL/min with a dissociation time
of 600 s. Chip surface regeneration following binding was performed with
bursts of regeneration mixture (50 mM EDTA pH 7.35, 600 mM imidazole pH
7.4, 6 mM NaAc pH 5.0, and 5% vol/vol HCl), followed by RB. Experiments
with HK were performed using a similar methodology, as described in detail
in SI Appendix. In brief, analytes were diluted to 250 nM into one vessel to
permit preincubation with 250 nM HK prior to injection.
Data were collected with the SPR program (Molecular Devices). Analyte
molecular weights were input to calculate the diffusion coefficient (m2/s), and
the target ligand molecular weights and surface density were input to calculate
RMAX. Cycle data were aligned to the start of injection, and the channel-channel
alignment box was checked. Data were analyzed with the QDAT program
(Molecular Devices). Each FC was zeroed to the RU prior to analyte titration.
Reference curves (FC-2) were subtracted, and the data were blanked to the
closest buffer blank. The kinetics and affinity of binding interactions were
obtained by fitting a simple ka/kd 1 or 2 binding site model. The assay was run
in triplicate, and the SEM was calculated using GraphPad Prism 8 software.
Data Availability. All study data are included in the article and supporting
information.
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